Aktis Oncology, Inc. (AKTS) Financial Statements

Aktis Oncology, Inc. (AKTS) reported trailing twelve-month revenue of $3.4M (down 2.7% year on year) and net income of -$24.1M, according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · read by EquiReason

AKTSAktis Oncology, Inc.Follow AKTS — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 874.9M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 12 Nov, in 19 days

Loading the filed annual statements…

USD millions · SEC XBRL

Aktis Oncology, Inc. — questions

What is Aktis Oncology, Inc.'s revenue?: $3.4M over the twelve months to the latest filing, down 2.7% year on year, from its 10-Q and 10-K filings.
What is Aktis Oncology, Inc.'s net income?: -$24.1M over the twelve months to .

Every figure on this page comes from Aktis Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.